secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001477932-24-006352
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab alleges unlawful proxy solicitation; stock plan and reverse split fail
--------------------------------------------------------------------------------

- Three director nominees re-elected despite significant against votes (Su-Leng Tan Lee: 4.1M for vs 6.3M against).
- Auditor JP Centurion & Partners reappointed with 10,720,634 votes for.
- 2024 Stock Incentive Plan not approved: 4,094,117 for, 6,382,176 against.
- Reverse stock split (1:2 to 1:10) not approved: 4,371,573 for, 6,378,201 against.
- Company alleges former officer/director directed unlawful proxy solicitation affecting Proposals 3&4; board authorized investigation, may pursue litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224006352/0001477932-24-006352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224006352/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-006352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer